Skip to content

EPS (Diluted) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.31+9.2%
Labcorp Holdings logo
Labcorp HoldingsLH
$3.35+32.9%
Quest Diagnostics logo
Quest DiagnosticsDGX
$2.24+15.5%
Natera, Inc. logo
Natera, Inc.NTRA
-$0.60-20.0%
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
-$0.71-77.5%
Personalis, Inc. logo
Personalis, Inc.PSNL
-$0.29-61.1%

Other financials

Income statement

See full
Revenue$71.1M-3.2%
Gross profit$21.5M-24.2%
Operating income-$34.6M-74.9%
Net income-$24.8M-115%

Balance sheet

See full
Cash & equivalents$23.4M-65.2%
Total debt$8.2M+40.5%
Total equity$1.0B-6.9%
Total assets$1.2B-4.1%

Cash flow

See full
Operating cash flow$7.1M+260%
CapEx$5.2M+10.3%
Free cash flow$1.9M+121%

Valuation

See full
Market cap$552.11M-7.1%
Enterprise value$536.92M+0.7%
P/S1.7×-0.3×

Profitability

See full
Gross margin38.7%-0.1pp
Operating margin-33.1%+17.4pp
Net margin-23%+43.3pp
FCF margin-36.9%

Returns & leverage

See full
Return on equity-6.8%+48.2pp
Debt / equity0.0×
Current ratio5.3×-1.0×

Where this comes from

Reported directly by Fulgent Genetics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare.

The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Fulgent Genetics, Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Fulgent Genetics, Inc.'s EPS (diluted)?
Fulgent Genetics, Inc. (FLGT) reported EPS (diluted) of -$0.80 in Q1 2026.
How has Fulgent Genetics, Inc.'s EPS (diluted) changed year-over-year?
Fulgent Genetics, Inc.'s EPS (diluted) decreased by 116.2% year-over-year, from -$0.37 to -$0.80.
What is the long-term trend for Fulgent Genetics, Inc.'s EPS (diluted)?
Over 4 years (2021 to 2025), Fulgent Genetics, Inc.'s EPS (diluted) has grown at a -41.2% compound annual growth rate (CAGR), from $16.38 to -$1.96.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.